Beckman Coulter Life Sciences has introduced the CytoFLEX mosaic Spectral Detection Module, the industry’s first modular approach to spectral flow cytometry. This innovative technology, compatible with existing CytoFLEX LX and S Flow Cytometers, delivers superior fluorescence sensitivity with up to 88 detection channels and can detect nanoparticles as small as 80 nm.

GRevvity, Inc. has secured US Food and Drug Administration approval for its Auto-Pure 2400 liquid handling platform with the T-SPOT.TB test, enhancing laboratory capabilities for latent tuberculosis detection. The technology, already available outside the US since 2024, enables higher testing volumes whilst maintaining clinical accuracy in this critical infectious disease diagnostic area.

AMSBIO has significantly enhanced its biofluid collection and processing capabilities, now offering researchers an expanded range of customizable human blood biospecimens from both healthy and disease-state donors. This development provides medical researchers with precise donor matching, comprehensive sample options, and specialized processing to meet exact research specifications.